Cel-Sci (United States)

American biotechnology company

CVM Nasdaq ISIN US1508377066 SEC CIK 725363 LEI 549300FIWOFSETIVMI17
Follow Cel-Sci (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$5.7M −0% vs same quarter last year
EPS, diluted −$0.47 +65.4% vs same quarter last year
Operating cash flow −$4M −2.3% vs same quarter last year
Operating income −$5.6M −1.2% vs same quarter last year
Net income by quarter
−$6.1M
−$7.1M
−$6.6M
−$5.7M
−$6.1M
−$5.5M
−$5.5M
−$5.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$40M−$30M−$20M−$10M$0$10MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$25.4M
FY24-−$26.9M
FY23-−$32.4M
FY22-−$36.7M
FY21-−$36.4M
FY20-−$30.3M
FY19-−$22.1M
FY18-−$31.8M
FY17-−$14.4M
FY16-−$11.5M
FY15-−$34.7M
FY14$264K−$27.4M
FY13$159.6K−$9.2M
FY12$254.6K−$15.5M
FY11$956.2K−$25.7M
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14−9721.4%−10359.6%
FY13−12450.1%−5746.8%
FY12−6772.3%−6078.8%
FY11−1881%−2689.1%
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$17.2M
FY24−$18.9M
FY23−$23.2M
FY22−$18.9M
FY21−$27.8M
FY20−$17.9M
FY19−$16.5M
FY18−$13.4M
FY17−$13.8M
FY16−$23.1M
FY15−$23.9M
FY14−$23M
FY13−$13.7M
FY12−$12.2M
FY11−$22.8M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cel-Sci (United States)
  • Healthcare median
−15000%−10000%−5000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearCel-Sci (United States)Healthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14−10359.6%−35.5%
FY13−5746.8%−37.1%
FY12−6078.8%−29.1%
FY11−2689.1%−27.9%